Large-Scale Profiling of HBsAg Levels in Chronic Hepatitis B for Functional Cure Development

The large-scale profiling of hepatitis B surface antigen (HBsAg) levels in patients with chronic hepatitis B (CHB) is a critical area of research aimed at advancing the development of therapies for achieving a functional cure. This study focused on quantitative hepatitis B surface antigen (qHBsAg) profiles, which serve as a key biomarker for understanding viral transcriptional activity and immune control in CHB patients.

### Key Findings:

1. **Baseline qHBsAg Levels**:

• Most patients with CHB exhibited relatively low qHBsAg levels at baseline, indicating limited viral activity and some degree of immune control.
• However, a significant proportion of patients had persistently high qHBsAg levels, suggesting ongoing viral replication and insufficient immune-mediated control.

2. **Longitudinal Trends**:

• qHBsAg levels generally declined very slowly over time, reflecting the indolent nature of antigen loss during chronic infection.
• Only a minority of patients achieved HBsAg seroclearance (complete loss of the surface antigen) during long-term follow-up, highlighting the challenges in achieving spontaneous functional cure.

3. **Clinical Predictors of HBsAg Seroclearance**:

• Certain factors were associated with lower qHBsAg levels and a greater likelihood of seroclearance:
• Older age.
• Absence of hepatitis B e antigen (HBeAg).
• Lower levels of viral replication.
• Higher alanine aminotransferase (ALT) levels relative to qHBsAg levels, which may indicate immune activity against the virus.

### Implications for Functional Cure Development:

• **Challenges in Achieving Functional Cure**:
• Many CHB patients have qHBsAg profiles that make spontaneous functional cure unlikely. This includes patients with high antigen burdens, who are less likely to respond to current or emerging antiviral treatments.
• The slow decline in qHBsAg levels over time underscores the need for therapies that can accelerate antigen loss and improve immune control.

• **Stratification of Patients**:
• qHBsAg levels can be used to stratify patients based on their likelihood of achieving seroclearance and their responsiveness to treatment. This biomarker provides valuable insights for tailoring therapeutic approaches.

• **Drug Development Considerations**:
• The study emphasizes the importance of accounting for baseline qHBsAg heterogeneity when designing novel therapies. Patients with high antigen burdens may require more potent or combination therapies to achieve functional cure.
• Emerging antiviral strategies should focus on targeting persistent viral activity and enhancing immune-mediated control in patients with high qHBsAg levels.

### Conclusion:

This research underscores the importance of large-scale profiling of qHBsAg levels in CHB patients to better understand the dynamics of antigen loss and to inform the development of more effective therapies. By identifying clinical predictors of seroclearance and highlighting the challenges posed by high antigen burdens, the study provides a roadmap for advancing therapeutic strategies aimed at achieving a functional cure for CHB.